SGX301 (synthetic hypericin) + Placebo
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Cutaneous T-Cell Lymphoma
Conditions
Cutaneous T-Cell Lymphoma
Trial Timeline
Dec 1, 2015 → Nov 1, 2020
NCT ID
NCT02448381About SGX301 (synthetic hypericin) + Placebo
SGX301 (synthetic hypericin) + Placebo is a phase 3 stage product being developed by Soligenix for Cutaneous T-Cell Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02448381. Target conditions include Cutaneous T-Cell Lymphoma.
What happened to similar drugs?
7 of 19 similar drugs in Cutaneous T-Cell Lymphoma were approved
Approved (7) Terminated (1) Active (11)
Hype Score Breakdown
Clinical
17
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02448381 | Phase 3 | Completed |
Competing Products
20 competing products in Cutaneous T-Cell Lymphoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ONTAK (denileukin difitox, DAB389IL-2) | Eisai | Approved | 43 |
| ONTAK | Eisai | Approved | 43 |
| E7777 9 mcg/kg | Eisai | Phase 3 | 40 |
| ONTAK | Eisai | Approved | 43 |
| Mogamulizumab | Kyowa Kirin | Approved | 47 |
| Mogamulizumab + Brentuximab vedotin | Kyowa Kirin | Phase 1 | 36 |
| Mogamulizumab | Kyowa Kirin | Phase 2 | 39 |
| KW-0761 + Vorinostat | Kyowa Kirin | Phase 3 | 40 |
| Enzastaurin | Eli Lilly | Phase 2 | 35 |
| Clopidogrel + Ticagrelor | AstraZeneca | Approved | 43 |
| Pembrolizumab | Merck | Phase 2 | 42 |
| Comparator: vorinostat | Merck | Pre-clinical | 26 |
| Pembrolizumab | Merck | Phase 2 | 39 |
| TR701 FA | Merck | Phase 2 | 35 |
| MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months | Merck | Phase 2 | 35 |
| Pembrolizumab | Merck | Phase 2 | 42 |
| Tulisokibart + Placebo | Merck | Phase 2 | 39 |
| Aspirin + Ipilimumab + Pembrolizumab | Merck | Phase 2 | 35 |
| Pembrolizumab + Mogamulizumab | Merck | Phase 2 | 42 |
| TR-701 FA + Linezolid | Merck | Phase 3 | 40 |